| Authors: |
Zhang H; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, 20878, USA. huixia.zhang1@astrazeneca.com., Tang W; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Sadow S; Biometrics, Vaccines and Immune Therapies, AstraZeneca, Wilmington, DE, USA., Baronio R; Biometrics, Vaccines and Immune Therapies, R&D, AstraZeneca, Cambridge, UK., Tullio AN; Global Patient Safety, Vaccines and Immune Therapies, R&D, AstraZeneca, Gaithersburg, MD, USA., Hirao L; Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Dzutseva V; Global Patient Safety, Vaccines and Immune Therapies, R&D, AstraZeneca, Gaithersburg, MD, USA., Chen CC; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA, USA., Kiazand A; Global Patient Safety, Vaccines and Immune Therapies, R&D, AstraZeneca, Gaithersburg, MD, USA., Chang LJ; Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Cohen TS; Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Gibbs M; Clinical Development, Vaccines and Immune Therapies, AstraZeneca, Cambridge, UK. |
